ALNY — ALNYLAM PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1178670 ·
Last close
$255.96
Market Cap
$34.25B
52W High
$495.55
52W Low
$197.81
ADV30
1,597,640
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,167,175,000 | 956,053,000 | 268,636,000 | 205,991,000 | 5,129,547,000 | 1,710,779,000 | 4,054,167,000 |
| Dec 2025 | 1,097,033,000 | 829,310,000 | 131,718,000 | 186,419,000 | 4,966,331,000 | 1,657,250,000 | 4,177,155,000 |
| Sep 2025 | 1,249,026,000 | 1,048,872,000 | 367,982,000 | 251,084,000 | 4,851,662,000 | 1,490,249,000 | 4,617,768,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$911,813,000
Investing CF
$74,942,000
Financing CF
$-377,001,000
CapEx
$-91,947,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$5.38
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,332,039,000
Inventory
$97,110,000
Receivables
$912,739,000
ST Investments
$1,599,829,000
EBIT TTM
$1,124,637,000
Pretax Income TTM
$799,565,000
Interest Exp TTM
$325,072,000
Analysts
24
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,804,182,016
EBITDA
$1,054,537,984
Free Cash Flow
$271,544,256
Enterprise Value
$32,954,992,640
Total Cash
$3,308,146,944
Total Debt
$2,987,489,024
Shares Out
133,809,118
Trailing EPS
$5.74
Book Value
$10.12
ROE
96.6%
ROA
12.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,713,937,000 | 501,578,000 | 313,747,000 | 4,966,331,000 | 4,177,155,000 | 789,176,000 | 524,080,000 |
| Dec 2024 | 2,248,243,000 | -176,885,000 | -278,157,000 | 4,239,983,000 | 4,172,895,000 | 67,088,000 | -8,312,000 |
| Dec 2023 | 1,828,292,000 | -282,175,000 | -440,242,000 | 3,829,880,000 | 4,050,524,000 | -220,644,000 | 104,156,000 |
| Dec 2022 | 1,037,418,000 | -785,072,000 | -1,131,156,000 | 3,546,359,000 | 3,704,582,000 | -158,223,000 | -541,274,000 |
TTM Snapshot
Revenues TTM
$1,862,294,000
NetIncome TTM
$-479,570,000
OpCashFlow TTM
$0
Assets (Latest)
$4,239,983,000
Forward EPS
$12.47
Max Pain — expiry 2026-12-18
max pain strike: $230.00 · spot: $253.79 · call oi: 2,916 · put oi: 2,199
Expected Move to 2026-12-18:
±$45.75
(18.03%) —
implied range
$208.04 –
$299.54
· ATM straddle on $250.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | $37.63B | $360.85 | — |
| ZTS | Zoetis Inc. | $29.36B | $71.05 | — |
| RPRX | Royalty Pharma plc | $25.92B | $58.21 | — |
| ROIV | Roivant Sciences Ltd. | $25.86B | $35.80 | — |
| INSM | INSMED Inc | $25.73B | $117.83 | — |
News headlines (Yahoo Finance, 1h cache)
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
2026-09-28 09:43 · Yahoo
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
2026-09-20 16:02 · Yahoo
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
2026-09-18 10:42 · Yahoo
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
2026-09-15 09:58 · Yahoo
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
2026-09-15 09:04 · Yahoo
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
2026-09-10 11:44 · Yahoo
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
2026-09-04 08:02 · Yahoo
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2026-09-02 12:00 · Yahoo
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
2026-08-31 15:40 · Yahoo
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
2026-08-31 12:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.